Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.
- Trial name
- NCT01541670
- Testing
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- Baxalta now part of Shire
Lupus Nephritis
Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
A randomized open-label study of fixed-dose versus concentration-controlled mycophenolate mofetil for treatment of active lupus nephritis.
- Trial name
- NCT03920059
- Testing
- Mycophenolate Mofetil
- Where
- Thailand
- Volunteers
- 2 people
- Sponsor
- Chulalongkorn University
Systemic Lupus Erythematosus, Cardiovascular Disease
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.
- Conditions
- Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
- Trial name
- NCT05440422
- Testing
- anifrolumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood.
- Conditions
- Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy
- Trial name
- NCT07855302
- Testing
- SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Seoul National University Hospital
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases.
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Trial name
- CARTIMMUNE (NCT06152172)
- Testing
- KYV-101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- David Porter
Systemic Lupus Erythematosus, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
This is an investigator-initiated trial aimed at assessing the safety of anti-CD19 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT06222853
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Depression, Systemic Lupus Erythematosus
Intervention to Improve Quality of Life in African American Lupus Patients
The goal of the proposed project is to enhance the Principal Investigator's research ability to conduct behavioral interventions for people with lupus.
- Trial name
- IQAN (NCT01837875)
- Testing
- Chronic Disease Self-Management Program (CDSMP), Mail-delivered arthritis kit, Support group
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Lupus Erythematosus, Systemic
Synergetic B-cell Immunomodulation in SLE - 2nd Study.
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment…
- Trial name
- SynBioSe-2 (NCT03747159)
- Testing
- Belimumab Injection
- Where
- 4 sites in Netherlands
- Volunteers
- 71 people
- Sponsor
- Leiden University Medical Center
Lupus Nephritis
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy.
- Trial name
- NCT07393451
- Testing
- SIM0278 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Systemic Lupus Erythematosus
A Model About the Response of Belimumab in SLE
A prospective, single-center cohort study aims to determine a predictive model of the response of belimumab at Week 48.
- Trial name
- MRBS (NCT04893161)
- Testing
- Belimumab
- Volunteers
- 72 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Systemic Lupus Erythematosus, Contraception
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
While the HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) program has been demonstrated to be effective in improving provider confidence, increasing contraception documentation, and facilitating…
- Trial name
- HOP-STEPsIRB (NCT05818254)
- Testing
- HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention, Routine Care
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Duke University
Systemic Lupus Erythematosus (SLE)
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
The natural history of Systemic lupus erythematosus (SLE) is characterized by relapses or flares alternated with periods of remission.
- Trial name
- 3TR-SLE2 (NCT05747651)
- Testing
- Blood sample, Urine sample, Saliva sample
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Brest
CAR-T Cell Therapy
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus…
- Trial name
- NCT05858684
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Venous Thrombosis
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
The purpose is to determine the hypercoagulable phenotype by thrombinography associated to an increased risk of symptomatic and objectively confirmed first venous thrombotic event.
- Trial name
- TACT (NCT02892565)
- Testing
- Blood sample
- Volunteers
- 122 people
- Sponsor
- Central Hospital, Nancy, France
Diabetic Nephropathies, Lupus Nephritis
Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease
During 1993 and 2006, a total of 987 patients older than 20 years underwent native kidney biopsy at the Renal Division of this hospital.
- Conditions
- Diabetic Nephropathies, Lupus Nephritis, Rapidly Progressive Glomerulonephritis, Chronic Kidney Diseases
- Trial name
- NCT03201406
- Where
- 2 sites in Taiwan
- Volunteers
- 837 people
- Sponsor
- National Taiwan University Hospital
Lupus Erythematosus, Systemic
Sirolimus Treatment Of Patients With SLE
Phase II Double-blind, placebo-controlled, randomized treatment trial with two arms: one SIROLIMUS arm with 92 patients and one placebo arm with 92 patients.
- Trial name
- STOPSLE (NCT04736953)
- Testing
- Sirolimus
- Volunteers
- 220 people
- Sponsor
- State University of New York - Upstate Medical University
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus…
- Trial name
- NCT06429800
- Testing
- ATA3219
- Where
- United States
- Sponsor
- Atara Biotherapeutics
Systemic Lupus Erythematosus
Alnuctamab for Refractory SLE (LATTE Study)
This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care…
- Trial name
- NCT07219563
- Testing
- Alnuctamab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lupus
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Study evaluating the safety and efficacy of a novel biologic in the treatment of systemic lupus erythematosus in male and female adults.
- Trial name
- NCT02265744
- Testing
- BMS-931699
- Where
- 121 sites in United States, Argentina and 21 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
Long-term Immunogenicity of a HPV Vaccine in SLE
To study the 5-year immunogenicity against a quadrivalent HPV vaccine in patients with SLE and healthy controls.
- Trial name
- NCT02477254
- Testing
- Vaccination
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Tuen Mun Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.